GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CanBas Co Ltd (TSE:4575) » Definitions » Debt-to-Revenue

CanBas Co (TSE:4575) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CanBas Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CanBas Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. CanBas Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. CanBas Co's annualized Revenue for the quarter that ended in Dec. 2023 was 円0.00 Mil.


CanBas Co Debt-to-Revenue Historical Data

The historical data trend for CanBas Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanBas Co Debt-to-Revenue Chart

CanBas Co Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.82 6.88 N/A N/A

CanBas Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of CanBas Co's Debt-to-Revenue

For the Biotechnology subindustry, CanBas Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanBas Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CanBas Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CanBas Co's Debt-to-Revenue falls into.



CanBas Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CanBas Co's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

CanBas Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


CanBas Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CanBas Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CanBas Co (TSE:4575) Business Description

Traded in Other Exchanges
N/A
Address
9 Toriyoko-cho, Shizuoka, JPN, 410-0891
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

CanBas Co (TSE:4575) Headlines

No Headlines